Appeal brought on 10 December 2025 by the European Commission against the judgment of the General Court (Fourth Camber) delivered on 24 September 2025 in Case T-309/23 Aliud Pharma GmbH v European Commission

(Case C-813/25 P)

(C/2026/467)

Language of the case: German

Parties

Appellant: European Commission (represented by: F. Erlbacher, L. Haasbeek, E. Mathieu and A. Spina, acting as Agents)

Other parties to the proceedings: Aliud Pharma GmbH, Biogen Netherlands BV

Form of order sought

The appellant claims that the Court should:

Grounds of appeal and main arguments

The European Commission relies on a single ground of appeal, alleging an error of law in the interpretation of Article 266 TFEU and Article 14(11) of Regulation (EC) No 726/2004. (1) The General Court made that error of law by ruling that the Commission was not able to issue Commission Implementing Decision C(2023) 3067 final of 2 May 2023 amending the marketing authorisation granted by Decision C(2014) 601 final for the medicinal product ‘Tecfidera’, which recognised an additional year of marketing protection.

(1)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1).